Literature DB >> 28864633

Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease.

Ryuichi Harada1,2, Aiko Ishiki2, Hideaki Kai3, Naomi Sato4, Katsutoshi Furukawa2,5, Shozo Furumoto6, Tetsuro Tago7, Naoki Tomita2, Shoichi Watanuki6, Kotaro Hiraoka6, Yoichi Ishikawa6, Yoshihito Funaki6, Tadaho Nakamura8, Takeo Yoshikawa9, Ren Iwata6, Manabu Tashiro6, Hironobu Sasano4, Tetsuyuki Kitamoto3, Kazuhiko Yanai9,6, Hiroyuki Arai2, Yukitsuka Kudo2, Nobuyuki Okamura6,8.   

Abstract

Clinical PET studies using 18F-THK5351 have demonstrated significant tracer retention in sites susceptible to tau burden in Alzheimer disease (AD). However, the in vivo PET signal to reflect tau aggregates remains controversial.
Methods: We examined the spatial pattern of tracer binding, amyloid-β, tau, and gliosis in an autopsy-confirmed AD patient who underwent 18F-THK5351 and 11C-Pittsburgh compound B PET before death.
Results: Regional in vivo 18F-THK5351 retention was significantly correlated with the density of tau aggregates in the neocortex and monoamine oxidase-B in the whole brain, but not correlated with that of insoluble amyloid-β. Furthermore, significant association was observed between the density of tau aggregates, monoamine oxidase-B, and glial fibrillary acidic protein, suggesting that neocortical tau would strongly influence the formation of reactive astrocytes.
Conclusion: 18F-THK5351 PET may have limited utility as a biomarker of tau pathology in AD; however, it could be used to monitor the neuroinflammatory processes in the living brain.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  Alzheimer’s disease; PET; imaging-pathology correlation; tau

Mesh:

Substances:

Year:  2017        PMID: 28864633     DOI: 10.2967/jnumed.117.197426

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  67 in total

1.  Comparison of Amyloid β and Tau Spread Models in Alzheimer's Disease.

Authors:  Hang-Rai Kim; Peter Lee; Sang Won Seo; Jee Hoon Roh; Minyoung Oh; Jungsu S Oh; Seung Jun Oh; Jae Seung Kim; Yong Jeong
Journal:  Cereb Cortex       Date:  2019-09-13       Impact factor: 5.357

Review 2.  The complexity of tau in Alzheimer's disease.

Authors:  Nima N Naseri; Hong Wang; Jennifer Guo; Manu Sharma; Wenjie Luo
Journal:  Neurosci Lett       Date:  2019-04-25       Impact factor: 3.046

3.  PET imaging of tau protein targets: a methodology perspective.

Authors:  Cristina Lois; Ivan Gonzalez; Keith A Johnson; Julie C Price
Journal:  Brain Imaging Behav       Date:  2019-04       Impact factor: 3.978

Review 4.  PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan.

Authors:  Tomohiro Kaneta
Journal:  Jpn J Radiol       Date:  2020-02-10       Impact factor: 2.374

5.  Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.

Authors:  Dean F Wong; Robert A Comley; Hiroto Kuwabara; Paul B Rosenberg; Susan M Resnick; Susanne Ostrowitzki; Cristina Vozzi; Frank Boess; Esther Oh; Constantine G Lyketsos; Michael Honer; Luca Gobbi; Gregory Klein; Noble George; Lorena Gapasin; Kelly Kitzmiller; Josh Roberts; Jeff Sevigny; Ayon Nandi; James Brasic; Chakradhar Mishra; Madhav Thambisetty; Abhay Mogekar; Anil Mathur; Marilyn Albert; Robert F Dannals; Edilio Borroni
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

6.  Tau-positron emission tomography correlates with neuropathology findings.

Authors:  Val J Lowe; Emily S Lundt; Sabrina M Albertson; Hoon-Ki Min; Ping Fang; Scott A Przybelski; Matthew L Senjem; Christopher G Schwarz; Kejal Kantarci; Bradley Boeve; David T Jones; R Ross Reichard; Jessica F Tranovich; Fadi S Hanna Al-Shaikh; David S Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Melissa E Murray
Journal:  Alzheimers Dement       Date:  2020-01-04       Impact factor: 21.566

7.  Differences in gray and white matter 18F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias.

Authors:  Hye Joo Son; Jungsu S Oh; Jee Hoon Roh; Sang Won Seo; Minyoung Oh; Sang Ju Lee; Seung Jun Oh; Jae Seung Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-14       Impact factor: 9.236

8.  Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.

Authors:  Jacob W Vogel; Niklas Mattsson; Yasser Iturria-Medina; Olof T Strandberg; Michael Schöll; Christian Dansereau; Sylvia Villeneuve; Wiesje M van der Flier; Philip Scheltens; Pierre Bellec; Alan C Evans; Oskar Hansson; Rik Ossenkoppele
Journal:  Hum Brain Mapp       Date:  2018-10-19       Impact factor: 5.038

9.  18F-THK 5351 and 11C-PiB PET of the Thai normal brain template.

Authors:  Chanisa Chotipanich; Supaporn Kongthai; Anchisa Kunawudhi; Chetsadaporn Promteangtrong; Attapon Jantarato
Journal:  Asia Ocean J Nucl Med Biol       Date:  2021

Review 10.  Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  Gérard N Bischof; Alessandra Dodich; Marina Boccardi; Thilo van Eimeren; Cristina Festari; Henryk Barthel; Oskar Hansson; Agneta Nordberg; Rik Ossenkoppele; Osama Sabri; B Frisoni G Giovanni; Valentina Garibotto; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.